Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
Following validation, the approach, which uses a deep convolutional neural network trained with almost 130,000 clinical images, could be developed into a smartphone app to detect skin cancer early.
